Dr. Soufian Meziyerh, Netherlands
Real-life tacrolimus levels are associated with biopsy-proven acute rejection after the first year post-kidney transplantation
Dr. David Rush, Canada
A 5-year prospective, randomized, open-label study of standard versus low-dose prolonged-release tacrolimus with or without ACEi/ARB in kidney transplantation
Dr. Aileen C Johnson, United States
Every 2-month belatacept maintenance therapy in kidney transplant recipients: 3-year follow-up of a randomized, non-inferiority trial
Dr. Christophe Masset, France
Modelling of kidney allograft function depending on Fast Tacrolimus Metabolizer status at different times post-transplantation